Article (Scientific journals)
Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin, Yves; Lampertz, S.; De Groote, D. et al.
1993In Leukemia, 7 (12), p. 2019-2025
Peer Reviewed verified by ORBi
 

Files


Full Text
57.pdf
Publisher postprint (478.25 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Aged; Antigens, CD/blood; Antigens, CD4/blood; Antigens, CD8/blood; Antigens, Differentiation, B-Lymphocyte/blood; Discriminant Analysis; Female; Humans; Immunoglobulin E/blood; Leukemia, Lymphocytic, Chronic, B-Cell/blood/immunology; Leukocyte Count; Lymphocytes; Male; Middle Aged; Receptors, Cell Surface/metabolism; Receptors, IgE/metabolism; Receptors, Interleukin-2/metabolism; Receptors, Transferrin/metabolism; Solubility
Abstract :
[en] We measured the soluble (s) receptors CD23, CD8, CD4, interleukin-2 receptor (IL-2R, CD25), and transferrin receptor (TfR, CD71), in normal serum and in patients with chronic lymphocytic leukemia (CLL) and evaluated them in relation to clinical and biological parameters of the disease, as well as serum immunoglobulin E (IgE). Compared to 31 normal individuals, 42 CLL patients had increased levels of sCD23 (98.4 +/- 127.7 versus 0.9 +/- 0.3 U/ml, p < 0.001), sIL-2R (6080 +/- 7030 versus 1420 +/- 640 pg/ml, p < 0.001), sTfR (12,100 +/- 11,250 versus 5000 +/- 1050 ng/ml, p < 0.001), and sCD8 (510 +/- 191 versus 234 +/- 89 U/ml, p < 0.001), but normal sCD4 levels. Mean sCD23 levels remained normal in patients with non-Hodgkin's lymphoma (other than small lymphocytic), Hodgkin's disease, hairy cell leukemia, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), multiple myeloma, or solid tumors. Advancing Rai clinical stage was associated with a progressive elevation of sCD23 (p < 0.001), while sCD8 (p < 0.05), sIL-2R (p < 0.001), and sTfR (p < 0.005) were highest in stage 2 patients. Discriminant analysis confirmed the value of soluble receptor determinations in the clinical evaluation of CLL patients. sCD23 correlated with sIL-2R (p < 0.001) and sTfR (p < 0.05) but not with sCD4 or sCD8, and displayed an inverse relationship with serum IgE (NS) and total gamma-globulin (p < 0.05). sIL-2R correlated with sCD23 (p < 0.001), sTfR (p < 0.001), sCD4 (p < 0.01), and sCD8 (p < 0.01). The lymphocyte count correlated with serum lactate dehydrogenase (LDH) (p < 0.05), sCD23 (p < 0.001) and sIL-2R (p < 0.01) but not sTfR, sCD8, or sCD4. Chemotherapy produced consistent reductions of sCD23 levels in two responding patients. We conclude that: (i) sCD23 is considerably elevated in CLL, correlates with the tumor mass and clinical stage, and could be helpful in monitoring these patients; and (ii) sIL-2R, sCD8, and sTfR levels are less specifically increased and could be influenced by other factors such as immune activation and erythropoiesis.
Disciplines :
Rheumatology
Hematology
Author, co-author :
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Lampertz, S.
De Groote, D.
Igot, D.
Malaise, Michel ;  Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Fillet, Georges ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Publication date :
1993
Journal title :
Leukemia
ISSN :
0887-6924
eISSN :
1476-5551
Publisher :
Nature Publishing Group, London, United Kingdom
Volume :
7
Issue :
12
Pages :
2019-2025
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 16 February 2009

Statistics


Number of views
198 (4 by ULiège)
Number of downloads
9 (0 by ULiège)

Scopus citations®
 
45
Scopus citations®
without self-citations
43

Bibliography


Similar publications



Contact ORBi